Last reviewed · How we verify
Ocrelizumab Dose 2 and Dose 3
Ocrelizumab Dose 2 and Dose 3 is a CD20-depleting monoclonal antibody Small molecule drug developed by Genentech, Inc.. It is currently in Phase 3 development for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.
Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.
At a glance
| Generic name | Ocrelizumab Dose 2 and Dose 3 |
|---|---|
| Sponsor | Genentech, Inc. |
| Drug class | CD20-depleting monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to CD20, ocrelizumab triggers the depletion of B cells, which are involved in the pathogenesis of multiple sclerosis and other autoimmune diseases. This depletion leads to a reduction in disease activity and symptoms.
Approved indications
- Relapsing forms of multiple sclerosis
- Primary progressive multiple sclerosis
Common side effects
- Infusion-related reactions
- Infections
- Neutropenia
Key clinical trials
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (PHASE2)
- PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases (PHASE1, PHASE2)
- Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset (PHASE4)
- A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab (PHASE4)
- A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (PHASE2)
- Ocrelizumab Access by Socio-Economic Status
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocrelizumab Dose 2 and Dose 3 CI brief — competitive landscape report
- Ocrelizumab Dose 2 and Dose 3 updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI
Frequently asked questions about Ocrelizumab Dose 2 and Dose 3
What is Ocrelizumab Dose 2 and Dose 3?
How does Ocrelizumab Dose 2 and Dose 3 work?
What is Ocrelizumab Dose 2 and Dose 3 used for?
Who makes Ocrelizumab Dose 2 and Dose 3?
What drug class is Ocrelizumab Dose 2 and Dose 3 in?
What development phase is Ocrelizumab Dose 2 and Dose 3 in?
What are the side effects of Ocrelizumab Dose 2 and Dose 3?
What does Ocrelizumab Dose 2 and Dose 3 target?
Related
- Drug class: All CD20-depleting monoclonal antibody drugs
- Target: All drugs targeting CD20
- Manufacturer: Genentech, Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Relapsing forms of multiple sclerosis
- Indication: Drugs for Primary progressive multiple sclerosis